共 251 条
[1]
Patterson TF(2016)Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America Clin Infect Dis 63 e1-e60
[2]
Thompson GR(2005)Posaconazole: clinical pharmacology and potential for management of fungal infections Expert Rev Anti Infect Ther 3 467-487
[3]
Denning DW(2016)Therapeutic drug monitoring of posaconazole: an update Curr Fungal Infect Rep 10 51-61
[4]
Fishman JA(2015)Pharmacokinetic and pharmacodynamic properties of oral voriconazole in patients with invasive fungal infections Pharmacotherapy 35 797-804
[5]
Hadley S(2013)Optimizing antifungal choice and administration Curr Med Res Opin 29 13-18
[6]
Herbrecht R(2015)Serum posaconazole levels among haematological cancer patients taking extended release tablets is affected by body weight and diarrhoea: single centre retrospective analysis Mycoses 58 432-436
[7]
Groll AH(2015)Subtherapeutic posaconazole exposure and treatment outcome in patients with invasive fungal disease Ther Drug Monit 37 766-771
[8]
Walsh TJ(2012)Factors influencing the pharmacokinetics of prophylactic posaconazole oral suspension in patients with acute myeloid leukemia or myelodysplastic syndrome Eur J Clin Pharmacol 68 987-995
[9]
Dekkers BG(2015)Clinical usefulness of therapeutic drug monitoring of voriconazole in a university hospital Enferm Infecc Microbiol Clin 33 298-302
[10]
Bakker M(2011)Observational study of the clinical efficacy of voriconazole and its relationship to plasma concentrations in patients Antimicrob Agents Chemother 55 4782-4788